Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsSTU:6IB -6.27%80 PB Ratio is 7.16 as of Jul. 20, 2026, which is 18% above its 10-year median of 6.05. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.19 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,231 Biotechnology companies, Innovent Biologics ranks worse than 80.26% on this metric.
The historical rank and industry rank for Innovent Biologics's PB Ratio or its related term are showing as below:
STU:6IB'
s PB Ratio Range Over the Past 10 Years
Min: 2.15 Med: 6.05 Max: 17.4
Current: 7.22
During the past 10 years, Innovent Biologics's highest PB Ratio was 17.40. The lowest was 2.15. And the median was 6.05.
STU:6IB's PB Ratio is ranked worse than 80.26% of 1231
companies
in the Biotechnology industry
Industry Median: 2.82
vs STU:6IB: 7.22
During the past 12 months, Innovent Biologics's average Book Value Per Share Growth Rate was 44.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Innovent Biologics was 27.90% per year. The lowest was -0.40% per year. And the median was 16.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Innovent Biologics PB Ratio Related Terms
Innovent Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Innovent Biologics (STU:6IB) has a PB Ratio of 7.16 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Innovent Biologics and its competitors. This is 18% above median its historical median of 6.05. Over the past decade, Innovent Biologics' PB Ratio has ranged from 2.15 to 17.40. According to the industry distribution chart, Innovent Biologics ranks #988 out of 1231 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Innovent Biologics' PB Ratio too high?
Innovent Biologics' current PB Ratio of 7.16 is 18% above median its 10-year median of 6.05. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 17.40. The Biotechnology industry median PB Ratio is 2.82. Innovent Biologics' value of 7.16 is 153.9% above this industry median. Based on the distribution chart, Innovent Biologics ranks #988 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #988 out of 1231 companies for PB Ratio. This places Innovent Biologics in the lower half of its industry. The industry median PB Ratio is 2.82. Innovent Biologics' value of 7.16 is 153.9% above this benchmark. Historically, Innovent Biologics' own PB Ratio has ranged from 2.15 to 17.40 over the past decade. While the company's 10-year median is 6.05 vs. the industry median of 2.82, Innovent Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current PB Ratio of 7.16 is 153.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current PB Ratio is 7.16, which is 18% above median its own 10-year median of 6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €9.69 — trading 13.4% below its estimated fair value. The current PB Ratio is 7.16, which is 18% above median its 10-year median of 6.05 and 153.9% above the Biotechnology industry median of 2.82. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current PB Ratio is 7.16 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €9.69 is trading 13.4% below its estimated GF Value™ of €11.19.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
PB Ratio: 7.16 (18% above median its 10-year median of 6.05)
GF Value™: €11.19 vs. price of €9.69 (13.4% below fair value)
Industry Position: 153.9% above the Biotechnology median (#988 of 1231)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
